华东医药10月27日公告，2025年第三季度实现营业收入109.89亿元，同比增长4.53%；归属于上市公司 股东的净利润9.33亿元，同比增长7.71%；基本每股收益0.5389元。前三季度实现营业收入326.64亿元， 同比增长3.77%；归属于上市公司股东的净利润27.48亿元，同比增长7.24%；基本每股收益1.5682元。 ...

Core Insights - East China Pharmaceutical reported a third-quarter revenue of 10.989 billion yuan, representing a year-on-year growth of 4.53% [1] - The net profit attributable to shareholders of the listed company was 933 million yuan, showing a year-on-year increase of 7.71% [1] Financial Performance - Third-quarter revenue: 10.989 billion yuan, up 4.53% year-on-year [1] - Net profit attributable to shareholders: 933 million yuan, up 7.71% year-on-year [1]

Core Insights - The company reported a revenue of 32.664 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 3.77% [1] - The net profit attributable to shareholders reached 2.748 billion yuan, with a year-on-year increase of 7.24% [1] - The company significantly increased its R&D investment in the pharmaceutical industry to 2.186 billion yuan, a growth of 35.99% year-on-year, with direct R&D expenses accounting for 16.21% of pharmaceutical industrial revenue [1] Pharmaceutical Industrial Performance - The pharmaceutical industrial segment achieved a revenue of 11.045 billion yuan, reflecting a year-on-year growth of 11.10% [2] - The net profit for this segment was 2.475 billion yuan, up 15.62% year-on-year [2] - Innovative product sales and agency service revenue reached 1.675 billion yuan, marking a substantial increase of 62% [2] Innovation and Product Development - The company has made significant breakthroughs in three core therapeutic areas: endocrinology, oncology, and autoimmune diseases [3] - The company has launched five new products and received six listings, with 18 IND approvals in China or the U.S. [3] - The CAR-T product, Zewokaiolun, has gained a strong market presence, with 170 effective orders placed in Q3 2025, surpassing the total orders from the previous year [2][3] Microbial Industrial Growth - The microbial industrial segment reported a revenue growth of 28.48% for the first three quarters of 2025 [4] - The company is focusing on four core business areas: xRNA raw materials, specialty APIs & intermediates, health & biological materials, and animal health [4] - The company aims to become a global leader in the aesthetic medicine sector, with a comprehensive product matrix covering various health and beauty applications [4][5] Clinical Research and Product Registration - The company has made progress in clinical research, with the KIO021 solution completing its first subject injection in China [5] - The YY001 botulinum toxin for improving glabellar lines has completed its BLA application and is currently under technical review [5] - The company is advancing its aesthetic medicine business with ongoing registration efforts in both domestic and international markets [4][5]

（编辑 任世碧） 证券日报网讯 10月27日晚间，华东医药发布2025年第三季度报告称，2025年第三季度公司实现营业收 入10，989，214，170.47元，同比增长4.53%；归属于上市公司股东的净利润为933，089，158.25元， 同比增长7.71%。 ...

Core Insights - The company reported a revenue of 32.664 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 3.77%, and a net profit attributable to shareholders of 2.748 billion yuan, up 7.24% year-on-year [1] - The company significantly increased its R&D investment to 2.186 billion yuan, a year-on-year increase of 35.99%, with direct R&D expenses reaching 1.767 billion yuan, up 53.76% [1] - The company achieved a revenue of 10.989 billion yuan in Q3 2025, a growth of 4.53%, and a net profit of 933 million yuan, up 7.71% year-on-year [1] Revenue and Profit Growth - The pharmaceutical industrial segment achieved a revenue of 11.045 billion yuan from January to September 2025, with a year-on-year growth of 11.10%, and a net profit of 2.475 billion yuan, up 15.62% [1] - In Q3 2025, the pharmaceutical industrial segment generated a revenue of 3.728 billion yuan, a growth of 14.95%, and a net profit of 894 million yuan, up 18.43% [2] Innovation and R&D - The sales and agency service revenue from innovative products reached 1.675 billion yuan in the first three quarters of 2025, marking a significant increase of 62% year-on-year [2] - The company has made breakthroughs in three core therapeutic areas: endocrinology, oncology, and autoimmune diseases, with over 90 innovative drug pipeline projects in progress [3] - The company received five marketing approvals and six applications accepted in 2025, with 18 INDs approved in China or the U.S. [3] Product Pipeline and Approvals - The company’s first-in-class drug for oncology, Mevanertinib, received approval in October 2025 for treating specific lung cancer patients [3] - The ADC drug HDM2027 received fast track designation from the FDA in October 2025, with IND approval in China [4] - The company is advancing its GLP-1 targeted products, with multiple applications submitted and clinical trials ongoing [4] Industrial Microbiology and Aesthetic Medicine - The industrial microbiology segment saw a revenue growth of 28.48% from January to September 2025, focusing on core business areas such as xRNA raw materials and health materials [5] - In the aesthetic medicine sector, the company aims to become a global leader, enhancing its operational efficiency and expanding its product matrix across various health and beauty domains [6] Future Outlook - The company is committed to a research-driven and patient-centered approach, aiming to accelerate the development and commercialization of innovative global products for sustainable high-quality growth [6]

格隆汇10月27日丨华东医药(000963.SZ)公布三季度报告，前三季营业收入326.64亿元，同比增长 3.77%，归属于上市公司股东的净利润27.48亿元，同比增长7.24%，归属于上市公司股东的扣除非经常 性损益的净利润26.9亿元，同比增长8.53%。 ...

Core Insights - The company reported steady revenue and profit growth for the first three quarters of 2025, with total revenue reaching 32.664 billion yuan, a year-on-year increase of 3.77%, and net profit attributable to shareholders of 2.748 billion yuan, up 7.24% [1] - Significant investment in R&D was noted, with expenditures rising to 2.186 billion yuan, a 35.99% increase, indicating a strong commitment to innovation [1] - The company’s innovative products are increasingly contributing to revenue, with sales from innovative products reaching 1.675 billion yuan, a substantial growth of 62% year-on-year [2] Financial Performance - For the first nine months of 2025, the pharmaceutical industrial segment achieved revenue of 11.045 billion yuan, a growth of 11.10%, and net profit of 2.475 billion yuan, up 15.62% [2] - In Q3 2025, the segment reported revenue of 3.728 billion yuan, a 14.95% increase, and net profit of 894 million yuan, an 18.43% rise [2] - The company maintained a resilient operational performance despite increased R&D investments, with quarterly revenue and profit showing a consistent upward trend [1] Product Development and Innovation - The company has made significant advancements in its core therapeutic areas, including endocrine, oncology, and autoimmune diseases, with over 90 innovative drug pipeline projects underway [4] - The ADC drug pipeline has shown promising progress, with several candidates receiving IND approvals in both China and the U.S. [5] - The company is preparing for negotiations regarding national medical insurance and commercial insurance for three innovative products, aiming to enhance drug accessibility and drive sales growth [3] Market Position and Strategy - The company has established a strong market presence with its CAR-T product, achieving significant order volumes that exceed previous year's totals [2] - The company’s innovative drug candidates are positioned to address various conditions, including diabetes and cancer, with several products nearing market entry [6][7] - The industrial microbiology segment has also shown robust growth, with a 28.48% increase in revenue, indicating a diversified growth strategy [9] Future Outlook - The company aims to continue its focus on research-driven, patient-centered approaches to foster sustainable high-quality growth [11] - The medical aesthetics business is expected to enhance its brand effect and core competitiveness through a global product matrix [10] - The ongoing development of innovative products and the expansion of market access are anticipated to provide solid momentum for future performance [11]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 第十一届董事会第四次会议决议公告 华东医药股份有限公司 证券代码：000963 证券简称：华东医药 公告编号：2025-097 1、审议通过《关于公司<2025年第三季度报告>的议案》 经审议，董事会认为《2025年第三季度报告》的内容真实、准确、 完整地反映了公司2025年第三季度经营的实际情况，不存在任何虚假 记载、误导性陈述或者重大遗漏，报告编制和审核的程序符合法律、 行政法规和中国证监会的相关规定。具体内容详见公司同日披露于巨 潮资讯网（www.cninfo.com.cn）的公司《2025年第三季度报告》。 表决结果：11票同意，0票反对，0票弃权。 1 该议案已经公司第十一届董事会审计委员会2025年第三次会议 审议通过。 2、审议通过《关于修订<内部审计管理制度>的议案》 华东医药股份有限公司（以下简称"公司"）第十一届董事会第四 次会议的通知于2025年10月23日以书面和电子邮件等方式送达各位 董事，于2025年10月27日（星期一）在公司会议室以现场并结合通讯 方式召开。 ...

Core Viewpoint - Huadong Medicine (000963) reported a steady growth in revenue and net profit for Q3 2025, indicating a positive performance trajectory in the pharmaceutical industry [1] Financial Performance - Q3 2025 revenue reached 10.989 billion yuan, a year-on-year increase of 4.53% [1] - Q3 2025 net profit was 933 million yuan, reflecting a year-on-year growth of 7.71% [1] - For the first three quarters of 2025, total revenue was 32.664 billion yuan, up 3.77% year-on-year [1] - Net profit for the first three quarters of 2025 stood at 2.748 billion yuan, with a year-on-year increase of 7.24% [1] - Basic earnings per share were reported at 1.5682 yuan [1] Product and Service Performance - Revenue from innovative product sales and agency services grew by 62% year-on-year [1] - The core subsidiary of the pharmaceutical industrial sector, Sino-American Huadong, saw a net profit increase of 15.62% year-on-year [1]

Core Viewpoint - Huadong Medicine (SZ 000963) announced the convening of its 11th fourth board meeting on October 27, 2025, to review the proposal for revising the "Internal Audit Management System" [1] Financial Performance - For the first half of 2025, Huadong Medicine's revenue composition was as follows: Commercial brokerage and agency accounted for 68.23%, pharmaceutical manufacturing for 33.94%, medical aesthetics for 4.57%, and other businesses for 0.77%, with inter-segment eliminations at -7.5% [1] Market Capitalization - As of the report, Huadong Medicine's market capitalization stood at 70 billion yuan [1]